RE: Pharmacy Manual (Revision to Regulations About Medicare Part D)

Transcription

1 Executive Office of Health and Human Services Office of Medicaid 600 Washington Street Boston, MA MASSHEALTH TRANSMITTAL LETTER April 2006 TO: FROM: Pharmacies Participating in Beth Waldman, Medicaid Director RE: (Revision to Regulations About Medicare Part D) This letter transmits revisions to the pharmacy regulations as a result of federal law enacting Medicare Part D and a new state law providing certain benefits to Medicare Part D-eligible members. The change applies to members who have Medicare and who can enroll in a Medicare Part D drug plan. Effective January 1, 2006, provides assistance with Medicare Part D copayments, in accordance with Chapter 175 of the Acts of Due to widespread and systemic problems across the Commonwealth with the implementation of Medicare Part D drug coverage, between January 7, 2006, and March 15, 2006, provided temporary emergency coverage for outpatient prescription drugs for individuals with both Medicare and. This coverage was available if a pharmacy was not able to bill a Medicare Part D plan or the Wellpoint/Anthem point-of-sale contingency plan. Once the temporary emergency coverage ended, effective March 16, 2006, began providing limited supplies of Medicare Part D-covered drugs, in accordance with Chapter 175 of the Acts of These emergency regulations were effective January 1, If you have any questions about the information in this transmittal letter please contact Affiliated Computer Systems (ACS) at NEW MATERIAL (The pages listed here contain new or revised language.) s vi and 4-3 through 4-10 OBSOLETE MATERIAL (The pages listed here are no longer in effect.) s vi and 4-3 through 4-6 transmitted by PHM-51 s 4-7 through 4-10 transmitted by PHM-53

2 Table of Contents vi Appendix A. Directory... A-1 Appendix B. Enrollment Centers... B-1 Appendix C. Third-Party-Liability Codes... C-1 Appendix D. Unit-Dose Drugs... D-1 Appendix W. EPSDT Services: Medical Protocol and Periodicity Schedule... W-1 Appendix X. Family Assistance Copayments and Deductibles... X-1 Appendix Y. REVS Codes/Messages... Y-1 Appendix Z. EPSDT Services Laboratory Codes... Z-1

3 4-3 Nonlegend Drug any drug for which no prescription is required by federal or state law. Pharmacy Online Processing System (POPS) the online, real-time computer network that adjudicates pharmacy claims, incorporating prospective drug utilization review, prior authorization, and member eligibility verification. Retail Establishment a physical place of business at which the provider sells legend, nonlegend, and other pharmacy products and services to the general public; a business conducted by mail, telephone, the Internet, or any other remote means does not constitute a retail establishment. Single-Source Drug a drug marketed or sold by one manufacturer or labeler under one proprietary name. Unit-Dose Packaging an individual drug product container usually consisting of foil, molded plastic, or laminate with indentations for a single solid oral dosage form, with any accompanying materials or components, including labeling. Each individual container fully identifies the drug and protects the integrity of the dosage. For purposes of 130 CMR , an assemblage of multiple, unlabeled single doses (traditional bingo cards or bubble packs ) is not unit-dose packaging. Unit-Dose-Return Fee a fee paid to the pharmacy for accepting returned drugs in unit-dose packaging in accordance with 130 CMR Unit-Dose Distribution System a means of packaging and/or distributing drugs in unit doses, devised by the manufacturer, packager, wholesaler, or retail pharmacist. A unit dose contains an exact dosage of medication and may also indicate the total daily dosage or the times when the medication should be taken. Such unit doses may or may not be in unit-dose packaging. Usual and Customary Charge the lowest price that a pharmacy charges or accepts from any health insurer or pharmacy benefit manager for the same quantity of a drug dispensed to a Massachusetts resident on the same date of service. When an insurer and the provider have a contract that specifies that the insurer will pay an average or similarly computed fixed amount for multiple therapeutic categories of drugs with different acquisition costs, the fixed amount will not be the provider s usual and customary charge. NDC number will identify drugs. Wholesale Acquisition Cost (WAC) a manufacturer s price published in a national price compendium or other publicly available source. Where no published price is identified as the WAC, the WAC is equal to the wholesale net unit price as published by First Data Bank. If no wholesale net unit price is published, the WAC is equal to the lower of the direct price or an adjusted average wholesale price.

4 : Eligible Members (A) (1) Members. covers pharmacy services only when provided to eligible members, subject to the restrictions and limitations described in regulations. 130 CMR specifically states, for each coverage type, which services are covered and which members are eligible to receive those services. (2) Recipients of the Emergency Aid to the Elderly, Disabled and Children Program. For information on covered services for recipients of the Emergency Aid to the Elderly, Disabled and Children Program, see 130 CMR (B) Member Eligibility and Coverage Type. For information on verifying member eligibility and coverage type, see 130 CMR : Provider Eligibility (A) All Providers. A pharmacy must be a participant in on the date of service in order to be eligible for payment. (B) In-State Providers. To be eligible for participation as a provider, a pharmacy must: (1) have a retail establishment located and doing business in the Commonwealth of Massachusetts; (2) be licensed by the Massachusetts Board of Registration in Pharmacy in accordance with M.G.L. c. 112 or be licensed by the Massachusetts Department of Public Health as a pharmacy in a clinic setting in accordance with M.G.L. c. 111; (3) be licensed by the federal Drug Enforcement Administration (DEA) and possess a DEA registration number; and (4) agree to use the agency s Pharmacy Online Processing System (POPS) in real-time mode to submit claims. (C) Out-of-State Providers. A provider that does not meet the requirements of 130 CMR (B) may participate in only if the provider meets the requirements of 130 CMR and: (1) is licensed by the Board of Registration in Pharmacy (or the equivalent) in the state in which the provider primarily conducts business; (2) possesses a DEA registration number. If a pharmacy is licensed to dispense only schedule VI drugs, a Massachusetts Controlled Substance Registration number may substitute for a DEA number); (3) participates in the Medicaid program or equivalent of the state in which the provider primarily conducts business; and (4) agrees to use s Pharmacy Online Processing System (POPS) in real-time mode to submit claims.

5 4-5 (D) Participation in the 340B Drug-Pricing Program for Outpatient Pharmacy Services. (1) Notification of Participation. A 340B-covered entity may provide drugs to members through the 340B drug-pricing program provided that it notifies the agency by submitting to the agency a copy of the form used to register with the Health Resources and Services Administration, Office of Pharmacy Affairs (OPA), as a 340Bcovered entity and, if applicable, a copy of the OPA form used to certify the contracted pharmacy services. The 340B-covered entity may provide and bill for 340B drugs to members, provided directly or by subcontract, after the agency confirms, in writing, its receipt of the 340B-covered entity s notification and a copy of its OPA registration form, in accordance with 130 CMR (D)(1). (2) Subcontracting for 340B Outpatient Pharmacy Services. (a) A 340B-covered entity may contract with a pharmacy provider to dispense 340B drugs for the 340B-covered entity s patients. All such subcontracts between the 340B-covered entity and a pharmacy provider must be in writing, ensure continuity of care, specify that the 340B-covered entity pays the pharmacy, specify that such payment constitutes payment in full for 340B drugs provided to members, be consistent with all applicable provisions of 130 CMR , and are subject to approval. The 340B-covered entity must comply with the requirements of 130 CMR (D)(1) by submitting to the agency a copy of the form used to register with the Health Resources and Services Administration, Office of Pharmacy Affairs (OPA), as a 340B-covered entity and a copy of the OPA form used to certify the contracted pharmacy services for the 340B drugpricing program. (b) The 340B-covered entity is legally responsible to the agency for the performance of any subcontractor. The 340B-covered entity must ensure that every pharmacy subcontractor is licensed by the Massachusetts Board of Registration in Pharmacy, is a pharmacy provider, and that services are furnished in accordance with pharmacy regulations at 130 CMR and all other applicable requirements, including but not limited to, those set forth in 130 CMR (3) Termination or Changes in 340B Drug-Pricing Program Participation. A 340B-covered entity must provide the agency 30 days advance written notice of its intent to discontinue, or change in any way material to the agency, the manner in which it provides 340B outpatient drugs for its patients. (4) Payment for 340B Outpatient Pharmacy Services. The agency pays the 340B-covered entity for pharmacy services, whether provided and billed directly or through a subcontractor, at the rates established in DHCFP regulations at CMR : Drugs and Medical Supplies Provided Outside of Massachusetts When provided out of state, drugs and medical supplies are reimbursable only if the member is temporarily out of state and requires drugs or medical supplies under the circumstances described in 130 CMR (130 CMR through Reserved)

6 : Prescription Requirements (A) Legal Prescription Requirements. The agency pays for legend drugs, nonlegend drugs, and those medical supplies listed at 130 CMR (B) only if the pharmacy has in its possession a prescription that meets all requirements for a legal prescription under all applicable federal and state laws and regulations. Each prescription, regardless of drug schedule, must contain the prescriber s unique DEA number. For Schedule VI drugs, if the prescriber has no DEA registration number, the prescriber must provide the state registration number on the prescription. (B) Emergencies. When the pharmacist determines that an emergency exists, the agency will pay the pharmacy for at least a 72-hour, nonrefillable supply of the drug in compliance with state and federal regulations. Emergency dispensing to a member who is enrolled in the Controlled Substance Management Program (CSMP) must comply with 130 CMR (C)(2). (C) Refills. (1) The agency does not pay for prescription refills that exceed the specific number authorized by the prescriber. (2) The agency pays for a maximum of 11 monthly refills, except in circumstances described in 130 CMR (C)(3). (3) The agency pays for more than 11 refills within a 12-month period if such refills are for less than a 30-day supply and have been prescribed and dispensed in accordance with 130 CMR (D). (4) The agency does not pay for any refill dispensed after one year from the date of the original prescription. (5) The absence of an indication to refill by the prescriber renders the prescription nonrefillable. (6) The agency does not pay for any refill without an explicit request from a member or caregiver for each filling event. The possession by a provider of a prescription with remaining refills authorized does not in itself constitute a request to refill the prescription. (D) Quantities. (1) Days Supply Limitations. The agency requires that all drugs be prescribed in a 30-day supply, unless the drug is available only in a larger minimum package size, except as specified in 130 CMR (D)(2). (2) Exceptions to Days Supply Limitations. The agency allows exceptions to the limitations described in 130 CMR (D)(1) for the following products: (a) drugs in therapeutic classes that are commonly prescribed for less than a 30-day supply, including but not limited to antibiotics and analgesics; (b) drugs that, in the prescriber's professional judgement, are not clinically appropriate for the member in a 30-day supply; (c) drugs that are new to the member, and are being prescribed for a limited trial amount, sufficient to determine if there is an allergic or adverse reaction or lack of effectiveness. The initial trial amount and the member's reaction or lack of effectiveness must be documented in the member's medical record;

7 4-7 (d) drugs packaged in such a way that the smallest quantity that may be dispensed is larger than a 30-day supply (for example, inhalers, ampules, vials, eye drops, and other sealed containers not intended by the manufacturer to be opened by any person other than the end user of the product); (e) drugs in topical dosage forms that do not allow the pharmacist to accurately predict the rate of the product s usage (for example, lotions or ointments); (f) products generally dispensed in the original manufacturer s packaging (for example, fluoride preparations, prenatal vitamins, and over-the-counter drugs); and (g) methylphenidate and amphetamine prescribed in 60-day supplies. (E) Prescription-Splitting. Providers must not split prescriptions by filling them for a period or quantity less than that specified by the prescriber. For example, a prescription written for a single 30-day supply may not be split into three 10-day supplies. The agency considers prescription-splitting to be fraudulent. (See 130 CMR (B)(6).) (F) Excluded, Suspended, or Terminated Clinicians. The agency does not pay for prescriptions written by clinicians who: (1) have been excluded from participation based on a notice by the U.S. Department of Health and Human Services Office of Inspector General; or (2) the agency has suspended, terminated, or denied admission into its program for any other reason : Covered Drugs and Medical Supplies (A) Drugs. The Drug List specifies the drugs that are payable under. In addition, the following rules apply. (1) Legend Drugs. The agency pays only for legend drugs that are approved by the U.S. Food and Drug Administration and manufactured by companies that have signed rebate agreements with the U.S. Secretary of Health and Human Services pursuant to 42 U.S.C. 1396r-8. Payment is calculated in accordance with DHCFP regulations at CMR 31.00: Prescribed Drugs. (2) Nonlegend Drugs. Payment by the agency for nonlegend drugs is calculated in accordance with DHCFP regulations at CMR 31.00: Prescribed Drugs. (B) Medical Supplies. (1) The agency pays only for the following medical supplies through POPS: (a) blood and urine testing reagent strips used for the management of diabetes; (b) disposable insulin syringe and needle units; (c) insulin cartridge delivery devices and needles or other devices for injection of medication (for example, Epipens); (d) lancets; (e) drug delivery systems for use with metered dose inhalers (for example, aerochambers); and (f) alcohol swabs. (2) Payment and coverage for all other medical supplies are described in durable medical equipment regulations at 130 CMR

8 : Limitations on Coverage of Drugs (A) Interchangeable Drug Products. The agency pays no more for a brand-name interchangeable drug product than its generic equivalent unless: (1) the prescriber has requested and received prior authorization from the agency for a nongeneric multiple-source drug (see 130 CMR ); and (2) the prescriber has written on the face of the prescription in the prescriber's own handwriting the words "brand name medically necessary" under the words "no substitution" in a manner consistent with applicable state law. These words must be written out in full and may not be abbreviated. (B) Drug Exclusions. The agency does not pay for the following types of drugs or drug therapy. (1) Cosmetic. The agency does not pay for legend or nonlegend preparations for cosmetic purposes or for hair growth. (2) Cough and Cold. The agency does not pay for legend or nonlegend drugs used solely for the symptomatic relief of coughs and colds, including but not limited to, those that contain an antitussive or expectorant as a major ingredient, unless dispensed to an institutionalized member. (3) Fertility. The agency does not pay for any drug used to promote male or female fertility. (4) Obesity Management. The agency does not pay for any drug used for the treatment of obesity. (5) Smoking Cessation. The agency does not pay for any drug used for smoking cessation. (6) Less-Than-Effective Drugs. The agency does not pay for drug products (including identical, similar, or related drug products) that the U.S. Food and Drug Administration has proposed, in a Notice of Opportunity for Hearing (NOOH), to withdraw from the market because they lack substantial evidence of effectiveness for all labeled indications. (7) Experimental and Investigational Drugs. The agency does not pay for any drug that is experimental, medically unproven, or investigational in nature. (8) Drugs for Sexual Dysfunction. The agency does not pay for drugs when used for the treatment of male or female sexual dysfunction. (C) Service Limitations. (1) covers drugs that are not explicitly excluded under 130 CMR (B). The limitations and exclusions in 130 CMR (B)(1) through (5) do not apply to medically necessary drug therapy for Standard enrollees under age 21. The Drug List specifies the drugs that are payable under. Any drug that does not appear on the Drug List requires prior authorization, as set forth in 130 CMR The Drug List can be viewed online at and copies may be obtained upon request. The agency will evaluate the priorauthorization status of drugs on an ongoing basis, and update the Drug List accordingly. See 130 CMR

9 4-9 (2) The agency does not pay for the following types of drugs or drug therapy without prior authorization: (a) immunizing biologicals and tubercular (TB) drugs that are available free of charge through local boards of public health or through the Massachusetts Department of Public Health (DPH); (b) nongeneric multiple-source drugs; and (c) drugs related to sex-reassignment surgery, specifically including but not limited to, presurgery and postsurgery hormone therapy. The agency, however, will continue to pay for post sex-reassignment surgery hormone therapy for which it had been paying immediately prior to May 15, (3) The agency does not pay any additional fees for dispensing drugs in a unitdose distribution system. The agency does, however, pay a unit-dose return fee in accordance with 130 CMR (4) The agency does not pay for any drug prescribed for other than the FDAapproved indications as listed in the package insert, except as the agency determines to be consistent with current medical evidence. (5) The agency does not pay for drugs that are provided as a component of a more comprehensive service for which a single rate of pay is established in accordance with 130 CMR : Insurance Coverage (A) Managed Care Organizations. The agency does not pay pharmacy claims for services to members enrolled in a managed care organization (MCO) that provides pharmacy coverage through a pharmacy network or otherwise, except for family planning pharmacy services provided by a non-network provider to a Standard MCO enrollee (where such provider otherwise meets all prerequisites for payment for such services). A pharmacy that does not participate in the member s MCO must instruct the member to take his or her prescription to a pharmacy that does participate in such MCO. To determine whether the member belongs to an MCO, pharmacies must verify member eligibility and scope of services through POPS before providing service in accordance with 130 CMR and (B) Other Health Insurance. When the member s primary carrier has a preferred drug list, the prescriber must follow the rules of the primary carrier first. The provider may bill the agency for the primary insurer s member copayment for the primary carrier s preferred drug without regard to whether the agency generally requires prior authorization, except in cases where the drug is subject to a pharmacy service limitation pursuant to 130 CMR (C)(2)(a) and (c). In such cases, the prescriber must obtain prior authorization from the agency in order for the pharmacy to bill the agency for the primary insurer s member copayment. For additional information about third party liability, see 130 CMR et seq.

10 4-10 (C) Medicare Part D. (1) Overview. Except as otherwise required in 130 CMR (C)(2) and (3), for members who have Medicare, the agency does not pay for any Medicare Part D drugs, or for any cost-sharing obligations (including premiums, copayments, and deductibles) for Medicare Part D drugs, whether or not the member has actually enrolled in a Medicare Part D drug plan. Medications excluded from the Medicare Part D drug program continue to be covered for members eligible for Medicare, if they are -covered medications. (2) Medicare Part D Transitional Coverage. pays for one-time supplies of prescribed medications, as described in 130 CMR (C)(2)(a) and (b). These payments will be authorized only if the member s Medicare prescription drug plan will not cover the prescribed medication at the time the prescription is presented, if the medication is a -covered medication, and for members who would otherwise be entitled to pharmacy benefits but for being eligible for Medicare prescription drug coverage. limits on pharmacy coverage, including prior authorization, do not apply to such one-time supplies. (a) Between January 1 and June 30, 2006, pays for a one-time 30-day supply of prescribed medications. After this supply of the prescribed medication, pays for a one-time 72-hour supply of the same prescribed medication. (b) Effective July 1, 2006, pays for a one-time 72-hour supply of prescribed medication. (3) Cost-Sharing Assistance for Dually-Eligible Members. Effective January 1, 2006, for dually-eligible members who are enrolled in a Medicare Part D plan, pays $1 toward a $2 copayment for generic drugs and $2 toward a $5 copayment for brand-name drugs. (130 CMR through Reserved)